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BACKGROUND: The validation of KRAS mutations as a negative marker of response to anti-epidermal growth factor receptor (EGFR)
antibodies has meant a seminal advance towards treatment individualisation of colorectal cancer (CRC) patients. However, as a KRAS
wild-type status does not guarantee a response to anti-EGFR antibodies, a current challenge is the identification of other biomarkers
of response. On the basis of pre-clinical evidence, we hypothesised that mitogen-activated protein kinase phosphatase-1 (MKP-1),
a phosphatase that inactivates MAPKs, could be a mediator of resistance to anti-EGFR antibodies.
METHODS: Tumour specimens from 48 metastatic CRC patients treated with cetuximab-based chemotherapy were evaluated for
KRAS and BRAF mutational status and MKP-1 expression as assessed by immunohistochemistry.
RESULTS: As expected, clinical benefit was confined to wild-type KRAS and BRAF patients. Mitogen-activated protein kinase
phosphatase-1 was overexpressed in 16 patients (33%) and was not associated with patient baseline clinicopathological
characteristics and KRAS mutational status. All patients with BRAF mutations (n¼3) had MKP-1 overexpression. Among KRAS wild-
type patients, MKP-1 overexpressors had a 7% response rate (RR), whereas patients not overexpressing MKP-1 had a 44% RR
(P¼0.03). Moreover, median time to progression was significantly longer in MKP-1 non-overexpressing patients (32 vs 13 weeks,
P¼0.009).
CONCLUSION: These results support the concept of MKP-1 as a promising negative marker of response to cetuximab-based treatment
in CRC patients with wild-type KRAS.
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Epidermal growth factor receptor (EGFR) is a transmembrane
tyrosine kinase receptor that, on ligand binding to its extracellular
domain, is activated and autophosphorylated. This activates
several intracellular signalling pathways that regulate crucial
oncogenic properties, mainly the PI3K–PTEN–AKT and the
mitogen-activated protein kinase (MAPK) RAS–RAF–MEK–
ERK cascade (Hanahan and Weinberg, 2000; Albanell et al, 2001;
Mendelsohn and Baselga, 2006). Moreover, EGFR inhibits the
activation of the other two MAPKs, namely, p38 MAPK and c-Jun
NH2-terminal kinase (JNK), which, contrary to ERK, drive
apoptotic signals (Dhillon et al, 2007; Takeuchi and Ito, 2010).
The unique position of EGFR as a regulator of several key
oncogenic pathways, together with the fact that EGFR is frequently
expressed in colorectal cancer (CRC), has made it an excellent
therapeutic target for the treatment of CRC patients.
The approval of two anti-EGFR monoclonal antibodies (moAbs),
cetuximab and panitumumab, for metastatic CRC (mCRC) has
dramatically improved the outcome of these patients. Both
cetuximab and panitumumab have shown response rates (RRs)
of 10–15% as single agents (Cunningham et al, 2004; Van Cutsem
et al, 2007) and B20% RR for cetuximab in combination with
chemotherapy in unselected advanced mCRC patients (Cunningham
et al, 2004). Moreover, anti-EGFR moAbs improve survival as
salvage therapy in advanced mCRC (Jonker et al, 2007;
Van Cutsem et al, 2007; Karapetis et al, 2008). The recent
validation of KRAS mutations as a biomarker of negative response
(or biomarker of resistance) to anti-EGFR therapies has meant a
major revolution in the field of targeted therapies and in the
treatment of mCRC patients (Amado et al, 2008; Karapetis et al,
2008; Bokemeyer et al, 2009; Van Cutsem et al, 2009). Activating
mutations of the downstream EGFR protein KRAS are present in
B40% of CRC patients. The most frequent KRAS mutations occur
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son codons 12 and 13, which impair ATPase activity, leading to a
permanent activation of the KRAS–RAF–MEK–ERK pathway,
despite EGFR blocking by cetuximab or panitumumab (Benvenuti
et al, 2007; Di Fiore et al, 2007; De Roock et al, 2008; Lievre et al,
2008). After preliminary results in a retrospective cohort analysis
(Lievre et al, 2008), the use of KRAS mutations as a marker of
resistance to anti-EGFR moAbs was supported by a retrospective
tumoural analysis of patients included in a randomised phase III
clinical trial of panitumumab monotherapy vs best supportive
care in chemotherapy-refractory mCRC patients. KRAS mutant
patients had a statistically significant lower RR (0% vs 17%) and
shorter progression-free survival (Amado et al, 2008). In the case
of cetuximab, results of a retrospective analysis of KRAS
mutational status in tumour biopsy samples of patients included
in several randomised phase III clinical trials have confirmed that
KRAS is a solid biomarker of resistance to cetuximab. The CO.17
clinical trial showed that clinical benefit to salvage cetuximab
monotherapy was confined to wild-type patients (Karapetis et al,
2008). In the OPUS and CRYSTAL trials, the addition of cetuximab
to conventional chemotherapy in first-line treatment for mCRC
patients showed no clinical benefit in KRAS mutated patients,
whereas KRAS wild-type patients had B60% of clinical responses
and longer progression-free survival with the addition of
cetuximab (Bokemeyer et al, 2009; Van Cutsem et al, 2009).
Therefore, the Food and Drug Administration has recently
restricted the indication for panitumumab and cetuximab to wild-
type KRAS mCRC patients. However, wild-type KRAS does
not guarantee response to anti-EGFR moAb, and a fraction of
KRAS wild-type patients will receive cetuximab or panitumumab
without deriving any benefit. Thus, it is now crucial to find other
markers of response that will help us in selecting KRAS wild-type
patients most likely to respond – or not respond – to anti-EGFR
therapy.
Although other mutationally activated protein kinases down-
stream of EGFR are being evaluated as potential biomarkers of
resistance to cetuximab, so far none of them has sufficient
supporting evidence to be routinely used in clinical practice. The
V600E BRAF mutation is present in B5–10% of CRC patients and
is mutually exclusive with KRAS mutations. In a hypothesis-
generating retrospective analysis of tumour biopsy samples of 113
patients treated with anti-EGFR moAb plus chemotherapy, BRAF-
mutated patients did not respond to therapy and had a shorter
progession-free survival and overall survival (OS) compared with
BRAF wild-type patients (Di Nicolantonio et al, 2008). Never-
theless, these results have not been confirmed when retrospectively
analysing the BRAF mutational status of a large phase III clinical
trial that evaluated chemotherapy, anti-angiogenic therapy and
cetuximab in first-line treatment of mCRC patients (Tol et al,
2009). The role of BRAF mutations as a prognostic factor, as well
as its low prevalence, will limit the confirmation of BRAF as a
marker of resistance to anti-EGFR therapies (Di Nicolantonio et al,
2008; Tol et al, 2009; Roth et al, 2010). Activating mutations of
PI3K are present in B10–30% of mCRC patients and have also
been suggested to be a negative biomarker of response to
cetuximab, although there are contradictory results from different
studies (Ogino et al, 2009; Prenen et al, 2009; Sartore-Bianchi et al,
2009). Upregulation of the PI3K–Akt axis by loss of PTEN is
theoretically another marker of resistance to anti-EGFR moAb.
Despite several positive retrospective series, the studies are limited
by a lack of standardised PTEN immunohistochemistry scoring
(Frattini et al, 2007; Loupakis et al, 2009; Sartore-Bianchi et al,
2009). Upregulation of EGFR ligands – amphiregulin and
epiregulin – expression has also been shown to be a marker of
resistance in an expression-array analysis (Khambata-Ford et al,
2007), and has been confirmed in a large retrospective study
(Jacobs et al, 2009). TP53 mutations are another potential
mechanism of resistance to anti-EGFR under evaluation (Oden-
Gangloff et al, 2009).
Mitogen-activated protein kinase phosphatases (MKPs), also
known as dual-specificity phosphatases, regulate the activity of
MAPKs (ERK, JNK and p38) by dephosphorylating both threonine
and tyrosine residues and therefore deactivating them (Wu, 2007;
Keyse, 2008). The MKP family is composed of 12 members, of
which MKP-1 (also referred to as dual-specificity phosphatase-1
and CL100) is the best characterised. MKP-1 is located in the
nucleus and regulates the three MAPKs with different substrate
preferences based on cell type and context (Chu et al, 1996;
Keyse (2008)). MKP-1 is overexpressed in human tumours such as
lung, breast and colon cancer, and has been involved in
tumourigenesis (Loda et al, 1996; Vicent et al, 2004; Rojo et al,
2009). Oncogenic activation of MKP-1 is mediated by EGFR
signalling by poorly understood mechanisms that include tran-
scriptional regulation mediated by p38 and ERK (Xing et al, 1996;
Li et al, 2001) and post-translational control by ERK (Brondello
et al, 1999; Lin et al, 2003; Lin and Yang, 2006). Interestingly, our
group and others are providing increasing evidence for a role of
MKP-1 in acquisition of resistance to anti-cancer therapy. The
molecular mechanism underlying MKP-1-mediated resistance to
anti-cancer drugs is in part due to the activation of JNK-driven
apoptosis by several anti-tumour agents such as anthracyclines,
taxanes, cisplatin, proteasome inhibitors and more recently anti-
EGFR drugs. High levels of MKP-1 inhibit JNK and counterbalance
the cytotoxic effects of such drugs (Sanchez-Perez et al, 1998, 2000;
Small et al, 2004, 2007; Wang et al, 2006, 2007; Workman and de
Bono, 2008; Rojo et al, 2009). With respect to anti-EGFR therapy,
in vitro results with the anti-EGFR drug AG1478 showed that MKP-
1-modulated JNK activation was critical for drug-induced apoptosis.
Moreover, ectopic expression of MKP-1 suppressed JNK-mediated
AG1417 apoptosis, leading to resistance to anti-EGFR therapy
(Takeuchi et al, 2009). Thus, MKP-1 overexpression is a potential
negative biomarker of response to certain anti-cancer agents
including anti-EGFR therapy. Furthermore, preliminary pre-clinical
work from our group found an association between high MKP-1
expression and resistance to cetuximab in CRC cell lines with wild-
type KRAS. MKP-1 expression was markedly lower in DiFi cells
(sensitive to cetuximab) compared with SW48 cells (resistant to
cetuximab) (A Dalmases and C Montagut, unpublished data).
On the basis of the extensive evidence of the implication of
MKP-1 in resistance to anti-cancer agents, as well as on the
preliminary pre-clinical evidence by our group and others of the
implication of MKP-1 in anti-EGFR therapy resistance (Takeuchi
et al, 2009), we hypothesised that MKP-1 expression in human
CRC tumours may be a marker of resistance to anti-EGFR moAb.
We therefore analysed the impact of MKP-1 on clinical outcome in
mCRC patients treated with cetuximab, with a special interest in
KRAS wild-type patients.
MATERIALS AND METHODS
Patient characteristics and clinical evaluation
We retrospectively selected 48 consecutive patients with histo-
logically confirmed mCRC treated with cetuximab-based chemo-
therapy at Hospital del Mar between 2004 and 2009. Patients’
selection criteria were based on tumour tissue availability for
molecular analysis. Cetuximab was administered as a loading dose
of 400mgm
 2, followed by 250mgm
 2 every week intravenously.
Clinical data and follow-up were obtained from the patients’
medical records. Tumour response was evaluated retrospectively
according to the response evaluation criteria in solid tumours
(Therasse et al, 2000). Patients with complete response, partial
response or stable disease were considered to have controlled
disease (CD) (Oden-Gangloff et al, 2009). This study was approved
by the Ethics Board of the Hospital and was performed according
to Institutional Guidelines.
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DNA was extracted from two 15-mm sections of paraffin-embedded
tissue using a QIAamp Tissue Kit (QIAGEN GmbH, Hilden,
Germany) according to the manufacturer’s protocol. In those cases
in which o50% of tumoural cells were present in the sample,
manual microdissection of tumoural tissue was performed.
Primers for KRAS (codons 12 and 13) and BRAF V600E ampli-
fication were designed using Primer Express software (Applied
Biosystems, Foster City, CA, USA) using NG_007524.1 (KRAS) and
NG_007873.1 (BRAF) sequences and were as follows: KRAS-F:
50-TTACGATACACGTCTGCAGTCAAC-30; KRAS-R: 50-AAAGAAT
GGTCCTGCACCAGTAATA-30; BRAF-F: 50-CGGCTCCTAAAGCAA
TGGC-30; BRAF-R: 50-CAGCATCTCAGGGCCAAAAA-30. DNA
amplification was performed by PCR under the following condi-
tions: initial denaturation for 10min at 951C, 40 cycles consisting
of: 1min at 951C, 1min at 541C (KRAS) or at 551C (BRAF) and
1min at 721C, and a final step at 721C for 10min. Mutation
analysis was performed by direct sequencing with BigDye v3.1
(Applied Biosystems) according to the manufacturer’s instructions
and analysed on an ABI3730XLSequencer (Applied Biosystems).
Immunohistochemistry
Immunohistochemistry was performed according to the metho-
dology previously described by our group (Rojo et al, 2009). In
brief, formalin-fixed paraffin-embedded 3mm tissue sections were
used for immunostaining using the Dako-Link platform. After
deparaffinisation in xylene and graded alcohols, heat antigen
retrieval was carried out in pH9 EDTA-based buffer (Dako,
Carpinteria, CA, USA). Endogenous peroxidase was blocked by
immersing the sections in 0.03% hydrogen peroxide for 5min.
Slides were incubated with anti-MKP-1 primary antibody for 1h at
room temperature, followed by incubation with the appropriate
anti-Ig horseradish peroxidase-conjugated EnVision polymer
(Dako) to detect antigen–antibody complexes. Sections were then
visualised with 3,30-diaminobezidine as chromogen and counter-
stained with haematoxylin. The specificity of the staining with
anti-MKP-1 antibody was controlled by pre-incubating the anti-
body with antigen (blocking peptide), and performing immuno-
staining of tissue sections and immunoblotting of BT-474 breast
cancer cell extracts. In addition to human specimens, renal tissues
were obtained from wild-type and MKP-1 gene knockout mice,
generously provided by Bristol-Myers Squibb Co. (Princeton, NJ,
USA), and used for validation of MKP-1 assay. These mouse
samples were processed with the same reagents and procedures as
used for human samples.
Immunohistochemical evaluation was carried out by three inde-
pendent observers (MI, MA and FR). To score a cell as positive,
nuclear staining was required for MKP-1 expression. The expression
was evaluated by calculating a semiquantitative histoscore (H-score)
that included the determination of both the percentage of stained
target cells and staining intensity (low, medium or high), as described
in Rojo et al, (2009). The final score was determined after applying a
weighting factor to each estimate and the following formula was used:
H-score¼(low%) 1þ(medium%) 2þ(high%) 3; the results
ranged from 0 to 300. MKP-1 was expressed in histologically normal
colon epithelial cells and the pattern and intensity of staining were
similar in all assayed specimens. MKP-1 overexpression was
considered when the intensity of staining in the nuclei of tumour
cells was higher than that observed in corresponding normal
epithelial cells (Rojo et al, 2009).
Statistical analysis
Fisher’s exact test was used to evaluate the association between
MKP-1 expression with dichotomous clinical and molecular
variables. Response to cetuximab-based therapy (responders vs
non-responders) according to KRAS or BRAF mutational status or
MKP-1 or EGFR expression was assessed by Fisher’s exact test. The
time to progression (TTP) was defined as the time from the start of
cetuximab-based treatment until documented tumour progression
or death. The Kaplan–Meier method was used to estimate TTP and
OS and the log-rank test to compare survival curves. All statistical
tests were conducted at the two-sided 0.05 level of significance.
Statistical analysis was performed with SPSS Statistical Software,
17.0 version (SPSS, Inc., Chicago, IL, USA).
RESULTS
Patient baseline characteristics and clinical response to
cetuximab
A total of 48 patients with mCRC treated with cetuximab-based
chemotherapy were included in this study. Of them, 47 had been
previously treated with chemotherapy, most of them (83%) had
previously received two or more lines of salvage treatment.
Administration of cetuximab was combined with irinotecan in 92%
of the patients. Evaluation of response to cetuximab based-therapy
showed that 11 patients responded to treatment (11 partial responses;
0 complete responses) with a median TTP of 27 weeks (range 1–66
weeks). Non-responders (stable disease in 15 patients; progression
disease in 22 patients) had a median TTP of 13 weeks (range 4–65
weeks). Patient baseline characteristics are shown on Table 1.
KRAS mutational status and clinical response to cetuximab
The mutational status of KRAS was assessed in all 48 patients
included in the study. KRAS mutations were found in 12
patients (25%). Such a low percentage compared with that in
previous reports is probably due to the fact that after Health
Authorities approval to limit the use of anti-EGFR moAb to KRAS
wild-type mCRC patients, KRAS mutant cases have not received
cetuximab-based therapy at our Institution. KRAS mutations were
as follows: G13D in five patients; G12D in three patients; G12V in
three patients; and G12A in one patient. In all, 11 out of 36 KRAS
wild-type patients (30%) responded to cetuximab, whereas none of
the 12 patients (0%) harbouring a KRAS mutation had a partial
response (P¼0.04). We also measured CD, as recently reported
(Oden-Gangloff et al, 2009). KRAS wild-type patients showed
statistically significant improvement in CD compared with mutant
KRAS patients (69% vs 8%, respectively). The median TTP for
KRAS wild-type patients was 25 weeks vs 8 weeks for KRAS mutant
patients (P¼0.01). Patients carrying KRAS-mutated tumours
tended to have shorter OS, although the difference did not reach
statistical significance (P¼0.1). Taken together, such findings
confirm that KRAS mutations inversely correlate with clinical
benefit from cetuximab therapy (Figure 1).
BRAF mutational status and clinical response to cetuximab
Three patients (6%) harboured BRAF mutations, which were
mutually exclusive with the presence of KRAS mutations. None of
the three patients with BRAF mutations responded to cetuximab
compared with 33% responses to cetuximab in BRAF wild-type
patients. This difference was not statistically significant, probably
because of the low incidence of BRAF (P¼0.54). Median TTP was
higher in wild-type BRAF patients than in mutant BRAF patients
(25 vs 7 weeks), although this correlation did not reach statistical
significance (P¼0.53).
MKP-1 expression and correlation with clinical and
molecular characteristics
Activated MKP-1 (i.e., nuclear staining), as assessed by immuno-
histochemistry, was overexpressed in 16 patients (33%; Table 1).
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nant cells. Histologically normal epithelial cells exhibited weak
and diffuse MKP-1 staining in the nuclei. A low level of
MKP-1 expression was also present in stroma cells (fibroblast
and endothelial cells) but it was not detected in lymphocytes
(Figure 2).
No significant correlation was found between MKP-1 expression
and clinical characteristics of patients, including age (o65 vs X65
years old), sex, tumour primary site (colon vs rectum), tumour size
(T1–2 vs T3–4), nodal status (positive vs negative), cetuximab
regimen (irinotecan vs oxaliplatin), number of previously received
chemotherapy metastatic lines (o2 vs X2 lines), hepatic, lung,
ascites and other metastases (present vs absent for each metastatic
site) and metastasectomy. MKP-1 expression was not linked to
expression of EGFR as assessed by immunohistochemistry
(P¼0.61). The expression of MKP-1 was not correlated with
KRAS mutational status as shown by 19% of MKP-1 over-
expressors harbouring a KRAS mutation vs 28% of MKP-1 non-
overexpressors with mutant KRAS (P¼0.72). It is worth noting
that all three patients with BRAF mutations had MKP-1 over-
expression (P¼0.04) (Table 1).
MKP-1 expression and clinical response to
cetuximab-based treatment in all patients
Only 1 of 16 patients with MKP-1 overexpression (6%) had a
partial response to treatment, whereas 10 of 32 non-overexpressing
MKP-1 patients (31%) responded to cetuximab, although the
correlation was not statistically significant (P¼0.074). Moreover,
CD was achieved in 19% of patients with MKP-1 overexpression,
compared with 72% of patients with low MKP-1 protein levels
(P¼0.001). The median TTP was lower in MKP-1 overexpressing
patients, compared with patients with non-overexpressed MKP-1
(13 vs 27 weeks; P¼0.43). No statistically significant differences
were observed by OS analysis (P¼0.5).
P=0.04 Mutant KRAS
12/48 (25%)
Response
No response
P=0.03 MKP-1 non-overexpressed
23/36 (64%)
MKP-1 overexpressed
13/36 (36%)
Response
No response
Mutant KRAS Wild-type KRAS
PR PR
SD
8%
SD
PD PD
40%
30%
A
30%
92%
MKP-1 non-overexpressing MKP-1 overexpressing
4% 7%
PR
SD
PR
SD
PD 78%
15%
PD
53% 78%
Wild-type KRAS
36/48 (75%)
0/12 (0) 11/36 (30%)
12/12 (100%) 25/36 (69%)
1/13 (7%) 10/23 (43%)
12/13 (92%) 13/23 (56%)
43%
Figure 1 KRAS mutations correlate with a lack of response to
cetuximab. In KRAS wild-type patients, mitogen-activated protein kinase
phosphatase-1 (MKP-1) overexpression is inversely correlated with
response to cetuximab. (A) The number (and percentage) of patients
with response and non-response (stable disease (SD)þprogressive disease
(PD)) to cetuximab are indicated according to KRAS mutational status and
MKP-1 expression. (B) Pie charts showing the percentage of patients
showing partial response (PR), SD and PD according to KRAS mutational
status and MKP-1 expression.
Table 1 Patient baseline characteristics and clinical response by MKP-1
status
Characteristics
(number of patients)
Number (%)
overexpressing MKP-1 P-value
Number of patients (n¼48) 16 (33)
Age (years)
o65 (n¼26) 7 (27) NS
X65 (n¼22) 9 (41)
Sex
Male (n¼31) 12 (39) NS
Female (n¼17) 4 (23)
Site of primary tumour
Colon (n¼36) 11 (30) NS
Rectum (n¼12) 5 (42)
Tumour size
T1–T2 (n¼2) 0 (0) NS
T3–T4 (n¼46) 16 (35)
Nodal status
Negative (n¼4) 2 (50) NS
Positive (n¼44) 14 (32)
Cetuximab regimen
Irinotecan based (n¼44) 15 (34) NS
Oxaliplatin based (n¼4) 1 (25)
Number of previous chemotherapy
o2( n¼8) 3 (37) NS
X2( n¼40) 13 (32)
Sites of metastasis
Hepatic (n¼33) 13 (39) NS
Lung (n¼21) 7 (33) NS
Peritoneal (n¼13) 5 (38) NS
Other (n¼16) 4 (25) NS
Metastasectomy
Yes (n¼6) 3 (50) NS
No (n¼42) 13 (31)
Mutational status
KRAS mutation (n¼12) 3 (25) NS
BRAF mutation (n¼3) 3 (100) 0.04
Clinical response
Partial response (n¼11) 1 (9)
Stable disease (n¼15) 2 (13)
Progression disease (n¼22) 13 (59 )
Abbreviations: MKP-1¼mitogen-activated protein kinase phosphatase-1; NS¼not
significant.
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KRAS wild-type patients
To address the clinically relevant need to identify KRAS wild-type
patients who may respond to cetuximab, we analysed MKP-1
expression in the subset of KRAS wild-type patients. Among KRAS
wild-type patients, only 1 out of 13 MKP-1 overexpressing patients
(7%) responded to cetuximab, whereas 10 out of 23 patients (43%)
with non-overexpressed MKP-1 responded to cetuximab (P¼0.03,
Figure 1). Furthermore, wild-type KRAS patients with low MKP-1
levels had 96% CD as compared with 22% CD in wild-type
KRAS patients with high MKP-1 levels (Po0.0001, Figure 1).
Patients with wild-type KRAS and overexpressed MKP-1 had
a shorter median TTP than wild-type KRAS patients with
MKP-1 low expression MKP-1 negative
MKP-1 intense expression
WT – MKP-1
40 kDa
BT474
Positive control Negative control
sc-1199P pre-incubation
MKP-1
Tubulin
MKP-1 intense expression
KO – MKP-1
BT474
sc-1199P
pre-incubation
Figure 2 Mitogen-activated protein kinase phosphatase-1 (MKP-1) expression in colon cancer. (A) Representative colon adenocarcinoma specimens
showing undetected (negative) MKP-1 expression, low expression and intense diffuse staining in tumour cells. Malignant cells expressed MKP-1 nuclear
staining; mild cytoplasmic staining is occasionally noted. Stroma cells (fibroblast and endothelial cells) also showed a low level of MKP-1 expression, which is
not detected in lymphocytes. (B) The specificity of immunostaining was probed by assaying renal tissue sections obtained from wild-type and MKP-1 gene
knockout mice. Specimens were processed using the same reagents and procedures as used in human samples. No staining was observed in knockout tissue
and intense nuclear expression was detected in renal tubes. (C) Positive and negative controls. The same tumour specimen considered as positive control
was assayed by pre-incubation of primary antibody with a specific blocking peptide, showing no staining. (D) MKP-1 expression explored by western blot
from BT-474 total lysates, using the same primary antibody and pre-incubated with a blocking peptide. The molecular size of MKP-1 was B40kD. The
protein was not detected under blocking peptide pre-incubation.
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KRAS wild-type individuals with non-overexpressed MKP-1 showed
a trend towards longer OS, which was not statistically significant
(P¼0.1). Such results suggest MKP-1 as a potential predictive factor
of failure to respond to cetuximab in KRAS wild-type patients.
MKP-1 expression and clinical response to cetuximab in
KRAS and BRAF wild-type patients
Given the increasing amount of evidence on a role for BRAF as a
marker of resistance to anti-EGFR moAb and to exclude a possible
bias, the predictive role of MKP-1 to cetuximab-based therapy was
assessed in KRAS and BRAF wild-type patients. Among KRAS/
BRAF wild-type patients, only 1 out of 10 patients (10%) with
overexpressed MKP-1 responded to cetuximab, compared with 10
out of 23 patients (43%) with non-overexpressed MKP-1 (P¼0.1).
It is of importance that CD was only observed in two patients with
high MKP-1 expression levels, whereas 22 of the 23 patients with
MKP-1 low expression had CD (P¼0.0001). Among KRAS and
BRAF wild-type patients, those with MKP-1 overexpression had
shorter TTP than patients with low MKP-1 levels (32 vs 13 weeks,
P¼0.006).
DISCUSSION
This study suggests MKP-1 as a novel and promising biomarker of
response to cetuximab in mCRC patients, particularly relevant to
certain KRAS wild-type patients who will not benefit from
cetuximab therapy.
The selection of patients to be treated with targeted therapies
based on useful and validated biomarkers is crucial to maximise
clinical efficacy while minimising toxicities and optimising the
use of currently constrained financial resources (Baselga, 2006;
McDermott et al, 2007; Workman and de Bono, 2008). The
validation of KRAS mutations as a negative biomarker of response
to anti-EGFR therapies such as cetuximab has meant a major
revolution in the treatment of CRC patients. The number of KRAS
mutations in this study (25%) was lower than that previously
reported, partly because of the fact that after June 2008, mutant
KRAS patients were not treated with cetuximab at our Institution
according to the results presented at the 44th ASCO Annual
Meeting (Bokemeyer et al, 2009; Van Cutsem et al, 2009). As
expected, in our series, clinical response was confined to wild-type
KRAS patients, who also had a statistically significantly longer TTP
than mutant KRAS patients.
In this study, BRAF mutations correlated with resistance to
cetuximab-based therapy, although the decrease in median TTP
was not statistically significant. We cannot rule out that this may
be related to an insufficient sample size to detect differences
in such a low-frequency occurring event. The response data
confirm the results of previous studies that showed that BRAF
mutations were linked to cetuximab efficacy in mCRC patients
(Di Nicolantonio et al, 2008). Nevertheless, recent results in mCRC
patients treated with chemotherapy, bevacizumab and cetuximab
as first-line therapy showed that BRAF mutations had a role as a
prognostic factor but not as a predictive marker of response to
cetuximab (Tol et al, 2009). Moreover, BRAF mutations have
prognostic value in stage II and III CRC patients (Roth et al, 2010).
Such apparently contradictory results may in part be explained by
the possible acquisition of BRAF mutations in advanced stages of
the disease and suggest that the role of BRAF as a predictive
marker of resistance to cetuximab might be restricted to patients
previously treated with chemotherapy. In this sudy, 83% of
patients had received two or more previous lines of chemotherapy,
and only one patient was treated with cetuximab as first-line
therapy for mCRC. Another controversial marker of anti-EGFR
moAb efficacy is the target itself. EGFR protein, as assessed by
immunohistochemistry, was overexpressed in 76% of tumours
(data not shown) and did not correlate with response to cetuximab
as previously demonstrated in other studies (Cunningham et al,
2004; Saltz et al, 2004; Chung et al, 2005).
Our data showed that overexpression of MKP-1, as assessed
by immunohistochemistry, was correlated with resistance to
cetuximab-based chemotherapy in mCRC patients, and suggests
a role for MKP-1 as a negative predictive biomarker of response
to cetuximab, particularly in KRAS wild-type patients. Although
this study is the first to correlate MKP-1 levels to cetuximab
resistance in CRC patients, the implication of other MKPs
in modulating response to anti-EGFR therapy has previously
been suggested. A gene expression profile analysis identified high
MKP-2 levels (also known as dual-specificity phosphatase-4) in
cetuximab-resistant patients (Khambata-Ford et al, 2007). More-
over, an elegant abstract presented at the 2009 ASCO Annual
Meeting showed that MKP-2 expression levels as determined by
quantitative reverse transcriptase PCR identifies a subgroup of
patients with shorter median OS to cetuximab therapy among
KRAS wild-type mCRC patients (De Roock et al, 2009).
As all patients included in this study received cetuximab in
combination with chemotherapy (irinotecan in 92% of the
patients), it cannot be excluded that MKP-1-based clinical outcome
is influenced, at least in part, by its interaction with chemotherapy.
Although so far there is no reported evidence of a role of MKP-1 in
conferring resistance to irinotecan, it will certainly be necessary to
conduct randomised clinical trials and extensive pre-clinical
modelling to exclude such hypotheses. A recently published paper
reports that other cetuximab predictive markers such as KRAS and
BRAF mutations do not preclude benefit from irinotecan or
oxaliplatin chemotherapy (Richman et al, 2009).
Molecular mechanisms underlying MKP-1-mediated resistance
to cetuximab are poorly understood. A possible explanation is
inhibition of JNK-mediated apoptosis by high MKP-1 levels, as has
recently been reported by Takeuchi et al (2009). On the other
hand, a recently published interesting hypothesis-generating study
supports p53 mutations as a potential marker of response to
cetuximab (Oden-Gangloff et al, 2009). MKP-1 has been shown to
be transcriptionally regulated by p53, and mutations of p53
abrogate p53-dependent transcription of MKP-1 in vitro (Yang and
Wu, 2004; Liu et al, 2008). Thus, it could be speculated that the
association between p53 mutations and better clinical outcome in
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Figure 3 Patients with mitogen-activated protein kinase phosphatase-1
(MKP-1) overexpression show shorter median time to progression (TTP)
than MKP-1 non-overexpressing patients in KRAS wild-type colon cancer
patients treated with cetuximab (13 vs 32 weeks, P¼0.009).
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scetuximab-treated patients is in part explained by a decrease in the
expression of MKP-1, although this molecular association needs to
be further characterised.
Interestingly, mutant KRAS tumours have been shown to
express high constitutive levels of MKP-1, MKP-2 and MKP-3,
probably as part of the regulatory feedback loop to attenuate the
high activation of ERK by mutant KRAS (Bild et al, 2006).
Moreover, functional studies in a KRAS mutant CRC murine
model has confirmed MKP-3 high levels, and high MKP-2 and
MKP-3 expressions have been described in human tumour biopsy
samples from mutant KRAS CRC patients (Haigis et al, 2008;
De Roock et al, 2009). However, in this study, we found that
MKP-1 basal levels were not linked to KRAS mutations. It is worth
noting that the presence of BRAF V600E mutations was associated
with MKP-1 overexpression in all the cases, although the number
of patients was insufficient to achieve a significant correlation.
Collectively, our results suggest a role for MKP-1 in predicting
failure to respond to cetuximab-based chemotherapy in KRAS
wild-type CRC patients.
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